Patients treated for constipation report more BM satisfaction with linaclotide

  • Taylor DCA & al.
  • J Clin Gastroenterol
  • 29 Jul 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Patients with constipation treated with linaclotide (Linzess) are more likely to report bowel movement (BM) satisfaction than those undergoing other treatments.

Why this matters

  • Understanding patient perceptions of treatment effects may help clinicians manage expectations and inform clinical decision making.

Study design

  • Researchers studied BM diaries completed by patients with either irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (N=1786; mean age, 46.8 years; 94.2% women; 83.3% white; BMs reported, 26,524), using logistic regression to analyze relationships among stool consistency, medication use, and BM satisfaction.
  • They classified BMs as loose or watery stools (LoWS), hard or lumpy stools (HoLS), or intermediate (neither LoWS nor HoLS).
  • Funding: Allergan; Ironwood Pharmaceuticals.

Key results

  • Overall BM satisfaction was highest for intermediate stools (61.2%), followed by LoWS (51.2%) and HoLS (19.4%).
  • Treatment with linaclotide was associated with higher odds of patient-reported BM satisfaction than treatment with other medications (OR, 1.23; P=.027).

Limitations

  • Results may not apply to uninsured and older populations.
  • The study did not assess other factors affecting BM satisfaction, such as straining, urgency, or sense of complete evacuation.